179 related articles for article (PubMed ID: 31095444)
1. PARP3 comes to light as a prime target in cancer therapy.
Rodriguez-Vargas JM; Nguekeu-Zebaze L; Dantzer F
Cell Cycle; 2019 Jun; 18(12):1295-1301. PubMed ID: 31095444
[TBL] [Abstract][Full Text] [Related]
2. PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.
Karicheva O; Rodriguez-Vargas JM; Wadier N; Martin-Hernandez K; Vauchelles R; Magroun N; Tissier A; Schreiber V; Dantzer F
Oncotarget; 2016 Sep; 7(39):64109-64123. PubMed ID: 27579892
[TBL] [Abstract][Full Text] [Related]
3. Characterization of DNA ADP-ribosyltransferase activities of PARP2 and PARP3: new insights into DNA ADP-ribosylation.
Zarkovic G; Belousova EA; Talhaoui I; Saint-Pierre C; Kutuzov MM; Matkarimov BT; Biard D; Gasparutto D; Lavrik OI; Ishchenko AA
Nucleic Acids Res; 2018 Mar; 46(5):2417-2431. PubMed ID: 29361132
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression.
Boehler C; Gauthier LR; Mortusewicz O; Biard DS; Saliou JM; Bresson A; Sanglier-Cianferani S; Smith S; Schreiber V; Boussin F; Dantzer F
Proc Natl Acad Sci U S A; 2011 Feb; 108(7):2783-8. PubMed ID: 21270334
[TBL] [Abstract][Full Text] [Related]
5. Parp3 promotes astrocytic differentiation through a tight regulation of Nox4-induced ROS and mTorc2 activation.
Rodriguez-Vargas JM; Martin-Hernandez K; Wang W; Kunath N; Suganthan R; Amé JC; Oliver FJ; Ye J; Bjørås M; Dantzer F
Cell Death Dis; 2020 Nov; 11(11):954. PubMed ID: 33159039
[TBL] [Abstract][Full Text] [Related]
6. New directions in poly(ADP-ribose) polymerase biology.
Bock FJ; Chang P
FEBS J; 2016 Nov; 283(22):4017-4031. PubMed ID: 27087568
[TBL] [Abstract][Full Text] [Related]
7. Identification and Functional Characterizations of N-Terminal α-N-Methylation and Phosphorylation of Serine 461 in Human Poly(ADP-ribose) Polymerase 3.
Dai X; Rulten SL; You C; Caldecott KW; Wang Y
J Proteome Res; 2015 Jun; 14(6):2575-82. PubMed ID: 25886813
[TBL] [Abstract][Full Text] [Related]
8. [Poly(ADP-ribose) polymerase (PARP): physiological and pathological roles].
Makogon NV; Aleksieieva IM
Fiziol Zh (1994); 2012; 58(3):95-112. PubMed ID: 22946318
[TBL] [Abstract][Full Text] [Related]
9. New perspectives on the plant PARP family: Arabidopsis PARP3 is inactive, and PARP1 exhibits predominant poly (ADP-ribose) polymerase activity in response to DNA damage.
Gu Z; Pan W; Chen W; Lian Q; Wu Q; Lv Z; Cheng X; Ge X
BMC Plant Biol; 2019 Aug; 19(1):364. PubMed ID: 31426748
[TBL] [Abstract][Full Text] [Related]
10. Pharmacology of ADP-ribosylation.
Schüler H; Ziegler M
FEBS J; 2013 Aug; 280(15):3542. PubMed ID: 23763848
[TBL] [Abstract][Full Text] [Related]
11. Dna is a New Target of Parp3.
Belousova EA; Ishchenko АA; Lavrik OI
Sci Rep; 2018 Mar; 8(1):4176. PubMed ID: 29520010
[TBL] [Abstract][Full Text] [Related]
12. Parp3 promotes long-range end joining in murine cells.
Layer JV; Cleary JP; Brown AJ; Stevenson KE; Morrow SN; Van Scoyk A; Blasco RB; Karaca E; Meng FL; Frock RL; Tivey T; Kim S; Fuchs H; Chiarle R; Alt FW; Roberts SA; Weinstock DM; Day TA
Proc Natl Acad Sci U S A; 2018 Oct; 115(40):10076-10081. PubMed ID: 30213852
[TBL] [Abstract][Full Text] [Related]
13. A key role for poly(ADP-ribose) polymerase 3 in ectodermal specification and neural crest development.
Rouleau M; Saxena V; Rodrigue A; Paquet ER; Gagnon A; Hendzel MJ; Masson JY; Ekker M; Poirier GG
PLoS One; 2011 Jan; 6(1):e15834. PubMed ID: 21264220
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of poly(ADP-ribosyl)ation in cancer: old and new paradigms revisited.
Lupo B; Trusolino L
Biochim Biophys Acta; 2014 Aug; 1846(1):201-15. PubMed ID: 25026313
[TBL] [Abstract][Full Text] [Related]
15. PARP3, a new therapeutic target to alter Rictor/mTORC2 signaling and tumor progression in BRCA1-associated cancers.
Beck C; Rodriguez-Vargas JM; Boehler C; Robert I; Heyer V; Hanini N; Gauthier LR; Tissier A; Schreiber V; Elofsson M; Reina San Martin B; Dantzer F
Cell Death Differ; 2019 Sep; 26(9):1615-1630. PubMed ID: 30442946
[TBL] [Abstract][Full Text] [Related]
16. Poly(adenosine diphosphate-ribose) polymerase as therapeutic target: lessons learned from its inhibitors.
Cseh AM; Fábián Z; Sümegi B; Scorrano L
Oncotarget; 2017 Jul; 8(30):50221-50239. PubMed ID: 28430591
[TBL] [Abstract][Full Text] [Related]
17. PARP3 is a sensor of nicked nucleosomes and monoribosylates histone H2B(Glu2).
Grundy GJ; Polo LM; Zeng Z; Rulten SL; Hoch NC; Paomephan P; Xu Y; Sweet SM; Thorne AW; Oliver AW; Matthews SJ; Pearl LH; Caldecott KW
Nat Commun; 2016 Aug; 7():12404. PubMed ID: 27530147
[TBL] [Abstract][Full Text] [Related]
18. The Development of a Biotinylated NAD
Ji M; Wang L; Xue N; Lai F; Zhang S; Jin J; Chen X
SLAS Discov; 2018 Jul; 23(6):545-553. PubMed ID: 29676938
[TBL] [Abstract][Full Text] [Related]
19. Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair.
Dantzer F; Amé JC; Schreiber V; Nakamura J; Ménissier-de Murcia J; de Murcia G
Methods Enzymol; 2006; 409():493-510. PubMed ID: 16793420
[TBL] [Abstract][Full Text] [Related]
20. Poly-ADP-ribose polymerases (PARPs) as a therapeutic target in the treatment of selected cancers.
Przybycinski J; Nalewajska M; Marchelek-Mysliwiec M; Dziedziejko V; Pawlik A
Expert Opin Ther Targets; 2019 Sep; 23(9):773-785. PubMed ID: 31394942
[No Abstract] [Full Text] [Related]
[Next] [New Search]
